Exact Sciences Corporation has received $-0.4 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-0.42 while the top line estimate is $-0.36 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 3.25%.
Exact Sciences Corporation reported better than expected with a surprise EPS of 16.28% or $0.07 during its most recent quarterly earnings. The Actual EPS was $-0.36 compared to the Estimated EPS of $-0.43.
In the last quarter, Exact Sciences Corporation reported Annual Earnings of $-0.36. Based on the filings, last years Annual Earnings was, $-1.71. In the last Quarter, EXAS reported a surprise Earnings per Share of 16.28% . The consensus estimate for current quarter is $-0.4 and for the current fiscal year, the estimate is $-1.7. For the Next fiscal year, the estimate is $-1.38 based on the consensus.
Exact Sciences Corporation (NASDAQ:EXAS) : On Tuesday heightened volatility was witnessed in Exact Sciences Corporation (NASDAQ:EXAS) which led to swings in the share price. The stock opened for trading at $18.12 and hit $19.09 on the upside , eventually ending the session at $18.95, with a gain of 4.81% or 0.87 points. The heightened volatility saw the trading volume jump to 2,181,064 shares. The 52-week high of the share price is $22.8 and the company has a market cap of $2,054 million. The 52-week low of the share price is at $4.67 .
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.